Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 1 22Phase 1/2 7Phase 3 4Phase EARLY_PHASE1 2Phase 4 1Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 4Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 27Vincristine 24Dexamethasone 22Rituximab 21Methotrexate 21Cytarabine 21Mercaptopurine 16Doxorubicin 15Etoposide 13Asparaginase 13Daunorubicin 12Prednisone 10Prednisolone 10Granulocyte Colony-Stimulating Factor 10Ifosfamide 8Idarubicin 8fludarabine 7pegylated granulocyte colony-stimulating factor 6Thioguanine 6Teniposide 6Vindesine 5Brentuximab Vedotin 5ibrutinib 4fludarabine phosphate 4Stem Cell Transplantation 4Gemcitabine 4Cisplatin 4Aprepitant 4zanubrutinib 3prednylidene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Sirolimus × Lymphoid × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡